Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 1013-1019

  Reddy, Prabashni ^a,b,c   Kalus, James S ^a,b   Caron, Michael F ^a,b   Horowitz, Sheryl ^b   Karapanos, Angiliki ^a   Coleman, Craig I ^a,b   Kluger, Jeffrey ^b   White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c ABT ASSOCIATES   (United States)

Author keywords

Amiodarone; Atrial septal pacing; Cardiac surgery; Cost effectiveness

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; COLESTYRAMINE; CYCLOSPORIN; PHENYTOIN; PLACEBO;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART PACING; HOSPITAL COST; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NAUSEA; OPEN HEART SURGERY; POSTOPERATIVE COMPLICATION;

ADMINISTRATION, ORAL; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CARDIAC SURGICAL PROCEDURES; COST-BENEFIT ANALYSIS; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 3543072180     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.1013.36132     Document Type: Article

References (27)

1. American Heart Association. 2002 heart and stroke statistical update. Dallas, TX: American Heart Association, 2001. Available from www.americanheart.org. Accessed August 7, 2002.
2. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001;135:1061-73.
3. Hravnak M, Hoffman LA, Saul MI, Zullo TG, Whitman GR. Resource utilization related to atrial fibrillation after coronary artery bypass grafting. Am J Crit Care 2002;11(3):228-38.
4. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002;106:75-80.
5. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1999;34:1262-347.
6. Daoud EG, Strickberger A, Ching Man K, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997;337:1785-91.
7. Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the atrial fibrillation suppression trial (AFIST): a randomized, placebo-controlled trial. Lancet 2001;357:830-6.
8. Lee SH, Chang CM, Lu MJ, et al. Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2000;70:157-61.
9. Guarnieri T, Nolan S, Gottlieb SO, Dudek A, Lowry DR. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the amiodarone reduction in coronary heart (ARCH) trial. J Am Coll Cardiol 1999;34(2):343-7.
10. Fan K, Lee KL, Chiu CSW, et al. Effects of biatrial pacing in preventing postoperative atrial fibrillation after coronary bypass surgery. Circulation 2000;102:755-60.
11. Connolly SJ, Cybulsky I, Lamy A, et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery. Am Heart J 2003;145(2):226-32.
12. Daubert JC, Mabo P. Atrial pacing for the prevention of postoperative atrial fibrillation: how and where to pace? J Am Coll Cardiol 2000;35(6):1423-7.
13. White CM, Caron MF, Kalus JS, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation. Circulation 2003;108(suppl II):200-6.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996:176-213.
15. Upsher-Smith. Pacerone (amiodarone) product information. Minneapolis, MN; 2000.
16. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analyzed? BMJ 2000;320:1197-200.
17. Hunink MGH, Bult JR, De Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998;18:337-46.
18. Kay GL, Sun GW, Aoki A, Prejean CA. Influence of ejection fraction on hospital mortality, morbidity, and costs for CABG patients. Ann Thorac Surg 1995;60:1640-51.
19. Hlatky MA, Boothroyd DB, Brooks MM, et al. Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. Am Heart J 1999;138:376-83.
20. Smith LR, Milano CA, Molter BS, Elbeery JR, Sabiston DC, Smith PK. Preoperative determinants of postoperative costs associated with coronary artery bypass graft surgery. Circulation 1994;90(5 pt 2): II124-8.
21. Ghali WA, Hall RE, Ash AS, Moskovitz MA. Identifying pre- and postoperative predictors of cost and length of stay for coronary bypass surgery. Am J Med Qual 1999;14(6):248-54.
22. Mauldin PD, Weintraub WS, Becker ER. Predicting hospital costs for first-time coronary artery bypass grafting from preoperative and postoperative variables. Am J Cardiol 1994;74:772-5.
23. Gerstenfeld EP, Hill MR, French SN, et al. Evaluation of right atrial pacing and biatrial pacing for the prevention of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1999;33:1981-8.
24. Reddy P, Dunn AB, White CM, Tsikouris JP, Giri S, Kluger J. An economic analysis of amiodarone versus placebo in the prevention of atrial fibrillation after open heart surgery. Pharmacotherapy 2002;22(1):75-80.
25. International Society of Pharmacoeconomics and Outcomes Research Advisory Panel. Methodological issues in conducting pharmacoeconomic evaluation-clinical studies. Available from http://www.ispor.org. Accessed May 28, 2002.
26. Spertus JA, Tooley J, Jones P, et al. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (eplerenone's neurohormonal efficacy and survival study). Am Heart J 2002;143(4):636-42.
27. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Circulation 2001;104:533-8.